Marvel Biosciences Corp. (MRVL.V)

0.1500 +0.0150 (+11.11%) At close: 02:10PM EDT

Marvel Biosciences Corp.

505 8th Avenue S.W.
Suit 420
Calgary, AB T2P 1G2
Canada
403-770-2469
https://marvelbiotechnology.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. J. Roderick Matheson	Executive Chairman & CEO	150k	N/A	N/A
Dr. Mark Williams M.B.A., Ph.D.	President, Chief Science Officer & Director	150k	N/A	1972
Mr. Harpreet Nijar C.M.A., CPA	Chief Financial Officer	82.5k	N/A	1988
Ms. Jacqueline Groot	Corporate Secretary	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company's lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson's disease. It targets diseases, such as depression, Alzheimer's disease, and liver fibrosis due to non-alcoholic steatohepatitis. The company has Collaboration agreement with FRAXA Research Foundation for the development of MB204. Marvel Biosciences Corp. is headquartered in Calgary, Canada.

Corporate Governance

Marvel Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.